STOCK TITAN

Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Lumos Pharma, Inc. (NASDAQ:LUMO) will participate in the Piper Sandler 35th Annual Healthcare Conference in New York City from November 28th – 30th. The company's management will present and host one-on-one meetings. A fireside chat is scheduled for November 30th at 2:30 PM EST, with a webcast available on the company's website. The presentation replay will be accessible for 90 days.
Positive
  • None.
Negative
  • None.

AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Company will participate in the Piper Sandler 35th Annual Healthcare Conference being held November 28th – 30th in New York City. Lumos Pharma management will present and host one-on-one meetings at the conference.

Piper Sandler 35th Annual Healthcare Conference: November 28th – 30th

 Title:Lumos Pharma Fireside Chat
 Date/Time:November 30th at 2:30 PM EST
 Webcast Link:Register here

The webcast can also be found on the Company’s website under Events & Presentations in the Investors & Media section. A replay of the presentation will be available for 90 days thereafter. Please contact your Piper Sandler salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$3.4B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

 


FAQ

What is the Piper Sandler 35th Annual Healthcare Conference?

The Piper Sandler 35th Annual Healthcare Conference is a notable event in the healthcare industry where companies present and engage in one-on-one meetings with investors.

Where can I find the webcast of Lumos Pharma's presentation?

The webcast can be accessed on the Company’s website under Events & Presentations in the Investors & Media section.

How long will the presentation replay be available?

The replay of the presentation will be available for 90 days after the event.

How can I schedule one-on-one meetings with Lumos Pharma's management team?

Please contact your Piper Sandler salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team.

Lumos Pharma, Inc.

NASDAQ:LUMO

LUMO Rankings

LUMO Latest News

LUMO Stock Data

24.02M
5.30M
34.68%
29.34%
3.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
AUSTIN

About LUMO

lumos pharma is an clinical stage biotechnology company focused on developing therapeutics for rare diseases